Canadian ALS advocates lobby for research investment
The Canadian amyotrophic lateral sclerosis (ALS) community is calling for the country’s government to invest CA$50 million (about $36…
Articles by Lindsey Shapiro, PhD
First Project Mosaic initiative: Developing patient-specific models
In a new initiative, Mosaic Neuroscience is teaming up with Ixcells Biotechnologies to develop patient-specific cell models that could…
New study may explain why ALS therapy BIIB078 didn’t work
The investigational antisense oligonucleotide (ASO) therapy BIIB078 may have failed in amyotrophic lateral sclerosis (ALS) clinical trials because it…
Lack of resources at FDA extends clinical hold on ALS drug NUZ-001
Due to a lack of resources and personnel, the U.S. Food and Drug Administration (FDA) has delayed its decision on…
Study ID’s specific microglia tied to disease progression in ALS
Immune cells in the brain exhibit distinct profiles in the brain and spinal cord of people with amyotrophic lateral…
Phase 3 trial of masitinib can now launch in US, some EU countries
AB Science has been cleared to start its confirmatory Phase 3 trial of masitinib for people with…
Clene working with FDA on accelerated approval for CNM-Au8
Clene has incorporated suggestions from the U.S. Food and Drug Administration (FDA) on its analysis plans for certain biomarker…
Antidepressants that inhibit REM sleep linked to ALS survival: Study
Antidepressants that suppress the rapid eye movement (REM) stage of sleep are associated with prolonged survival in people with…
Lou Gehrig Day on June 2 to honor baseball player’s ALS legacy
Supporters will celebrate the 5th annual Lou Gehrig Day on June 2. The yearly event honors the legacy of…
Clene eyeing regulatory submission for CNM-Au8 in ALS by year’s end
Clene Nanomedicine is on track to seek accelerated approval of CNM-Au8 for treating amyotrophic lateral sclerosis (ALS)…